MONTE ROSA THERAPEUTICS ($GLUE) posted quarterly earnings results for Q3 2026 on Thursday, November 5th. The company reported earnings of $0.03 per share, beating estimates of -$0.30 by $0.33. The company also reported revenue of $54,370,000, beating estimates of $30,345,000 by $24,025,000.
You can see Quiver Quantitative's $GLUE stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
MONTE ROSA THERAPEUTICS Insider Trading Activity
MONTE ROSA THERAPEUTICS insiders have traded $GLUE stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.
Here’s a breakdown of recent trading of $GLUE stock by insiders over the last 6 months:
- FILIP JANKU (Chief Medical Officer) has made 0 purchases and 4 sales selling 53,252 shares for an estimated $1,152,374.
- SHARON TOWNSON (Chief Scientific Officer) has made 0 purchases and 5 sales selling 18,000 shares for an estimated $376,069.
- JENNIFER CHAMPOUX (Chief Operating Officer) has made 0 purchases and 5 sales selling 13,053 shares for an estimated $271,417.
- ANTHONY M. MANNING sold 10,000 shares for an estimated $231,100
- MARKUS WARMUTH (President & CEO) sold 9,500 shares for an estimated $220,218
- MATTHEW BOWEN (Principal Accounting Officer) sold 13 shares for an estimated $137
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
MONTE ROSA THERAPEUTICS Hedge Fund Activity
We have seen 105 institutional investors add shares of MONTE ROSA THERAPEUTICS stock to their portfolio, and 81 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ added 2,140,983 shares (+31.9%) to their portfolio in Q2 2026, for an estimated $51,811,788
- BRAIDWELL LP added 1,503,246 shares (+158.5%) to their portfolio in Q2 2026, for an estimated $36,378,553
- BLACKROCK, INC. added 1,205,403 shares (+21.4%) to their portfolio in Q2 2026, for an estimated $29,170,752
- AMERICAN CENTURY COMPANIES INC removed 1,186,801 shares (-42.2%) from their portfolio in Q2 2026, for an estimated $28,720,584
- VESTAL POINT CAPITAL, LP added 996,535 shares (+27.7%) to their portfolio in Q2 2026, for an estimated $24,116,147
- SILVERARC CAPITAL MANAGEMENT, LLC removed 893,745 shares (-44.6%) from their portfolio in Q2 2026, for an estimated $21,628,629
- WOODLINE PARTNERS LP added 888,388 shares (+1192.5%) to their portfolio in Q2 2026, for an estimated $21,498,989
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
MONTE ROSA THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $GLUE recently. We have seen 2 analysts offer price targets for $GLUE in the last 6 months, with a median target of $33.0.
Here are some recent targets:
- Michael Schmidt from Guggenheim set a target price of $35.0 on 06/30/2026
- Brian Cheng from JP Morgan set a target price of $31.0 on 05/11/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
